Who is sponsoring NCT02570191?

NCT02570191 is sponsored by Hoffmann-La Roche.

What condition does NCT02570191 study?

NCT02570191 studies Hepatitis B, Chronic.

What drugs are being tested in NCT02570191?

Interventions: Peginterferon alfa-2a.

What is the status of NCT02570191?

NCT02570191 is currently COMPLETED.

Last reviewed 2016-11-01 · How we verify

An Open-label, Multicenter, National, Not-randomized Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (40 KD) (PEGASYS) in Patients With HBeAg-negative Chronic Hepatitis B

NCT02570191 Phase 4 COMPLETED

This study will evaluate the efficacy, safety, and tolerability of PEGASYS in participants with HBeAg-negative chronic HBV. The anticipated time on study treatment is 48 weeks, and the target sample size is 60 individuals.

Details

Lead sponsor	Hoffmann-La Roche
Phase	Phase 4
Status	COMPLETED
Enrolment	60
Start date	2004-11
Completion	2007-02

Conditions

Hepatitis B, Chronic

Interventions

Peginterferon alfa-2a

Primary outcomes

Efficacy: Hepatitis B Virus - Deoxy ribonucleic acid (HBV-DNA) less than (<)20,000 Copies per milliliter (copies/mL) At End of Follow-Up — 72 Weeks
Alanine Transaminase (ALT) Normalization at the End of Follow-Up — 72 Weeks

Countries

Bulgaria